

**DIAGNOSTICS &
MONITORING**

**NICE UK
DIAGNOSTIC
ASSESSMENT
PROGRAMME - ICM**

Key Results:

- **ONLY** Reveal LINQ is recommended in CS patients after external ECG monitoring.
- LINQ is cost-effective for stroke prevention in CS/TIA patients.
- Including FocusOn is also cost-effective.

Background on NICE UK: (For Customers Unfamiliar with NICE UK)

- NICE is one of the most highly regarded HTA bodies in the world
 - **HTA: Health Technology Assessment**
- Many other HTA bodies adopt their advice or are greatly influenced by it
- NICE has assessed the clinical effectiveness and cost-effectiveness of ICMs in CS



Source: NICE Diagnostics Guidance 41: Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke. September 2020 © NICE 2020

Link to the guidance: <https://www.nice.org.uk/guidance/dg41>

THE ECONOMIC MODEL USED BY NICE
DG41 ESTIMATES THAT THE NUMBER
OF STROKES THAT COULD BE AVOIDED
BY USING AN ICM IS 52 PER 1,000 PEOPLE
WITH CRYPTOGENIC STROKE¹



55%

We see a 55% decreased risk of recurrent stroke in patients who undergo prolonged cardiac monitoring vs conventional cardiac monitoring²



€43,129

Direct healthcare cost of a stroke per patient³

1. NICE Diagnostics Guidance 41: Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke. September 2020 © NICE 2020
2. Tsvigoulis G, Katsanos AH, Grory BM, et al. Prolonged Cardiac Rhythm Monitoring and Secondary Stroke Prevention in Patients With Cryptogenic Cerebral Ischemia. *Stroke*. Published online June 20, 2019
3. Kominsky-Rabas PL, Heuschmann PU, Marschall D. et al. Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry. *Stroke*. May 2006;37(5): 1179-1183

Watch the Webinar: <https://www.medtronic.com/uk-en/c/cryptogenic-stroke-af.html>

NICE DG41 Guidance Text


REVEAL LINQ™ INSERTABLE CARDIAC MONITOR IS THE ONLY ICM TO HAVE SUFFICIENT EVIDENCE TO BE RECOMMENDED BY NICE DIAGNOSTICS GUIDANCE 41.

Reveal LINQ™ is recommended as an option to help to detect atrial fibrillation after cryptogenic stroke, including transient ischaemic attacks (TIA), only if:

- non-invasive electrocardiogram (ECG) monitoring has been done and
- a cardiac arrhythmic cause of stroke is still suspected.

REVEAL LINQ™ IS LIKELY TO BE A COST-EFFECTIVE USE OF NHS RESOURCES:

- When compared to conventional follow-up, **Reveal LINQ™** was found to have an **ICER of £10,342** (Threshold for NICE DG 41 recommendation is less than £20,000).
- **FOCUSON™** monitoring & triaging service was also determined to be a cost-effective use of NHS resources.



Source: NICE Diagnostics Guidance 41: Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke. September 2020 © NICE 2020

Watch the Webinar: <https://www.medtronic.com/uk-en/c/cryptogenic-stroke-af.html>

Available Resources

- ✓ Patient Selection Guidance
- ✓ Localized Economic Value Documents and Calculators
- ✓ A Radcliffe Cardiology Webinar on NICE Recommendation
- ✓ In-Depth Education Resources
- ✓ On-Demand Referral Pathway Workshops



Watch the Webinar: <https://www.medtronic.com/uk-en/c/cryptogenic-stroke-af.html>

THANK YOU

BRIEF STATEMENT

See the device manual for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. If using an MRI SureScan™ device, see the MRI SureScan™ technical manual before performing an MRI. For further information, contact your local Medtronic representative and/or consult the Medtronic website at www.medtronic.eu.

For applicable products, consult instructions for use on manuals.medtronic.com. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.

Medtronic and the Medtronic logo are trademarks of Medtronic. All other brands are trademarks of a Medtronic company.

Medtronic

Europe

Medtronic International Trading Sari.
Route du Molliau 31
Case Postale
CH- 1131 Tolochenaz
www.medtronic.eu
Tel +410 21802 70 00
Fax. +410 21802 79 00

medtronic.eu

United Kingdom/Ireland

Medtronic Limited
Building 9
Croxley Park
Hatters Lane
Watford
Herts WD18 8WW
www.medtronic.co.uk
Tel: + 440 1923 212213
Fax: +44 0 1923 241004